SC 13G/A: Alaunos Therapeutics, Inc.

Ticker: TCRT · Form: SC 13G/A · Filed: Feb 14, 2024 · CIK: 1107421

Alaunos Therapeutics, INC. SC 13G/A Filing Summary
FieldDetail
CompanyAlaunos Therapeutics, INC. (TCRT)
Form TypeSC 13G/A
Filed DateFeb 14, 2024
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sc-13g-a

AI Summary

SC 13G/A filing by Alaunos Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

What type of filing is this?

This is a SC 13G/A filing submitted by Alaunos Therapeutics, INC. (ticker: TCRT) to the SEC on Feb 14, 2024.

What is the risk level of this SC 13G/A filing?

This filing has been assessed as low risk.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti).

How long is this filing?

Alaunos Therapeutics, INC.'s SC 13G/A filing is 6 pages with approximately 1,866 words. Estimated reading time is 7 minutes.

Where can I view the full SC 13G/A filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,866 words · 7 min read · ~6 pages · Grade level 8.3 · Accepted 2024-02-14 12:43:20

Key Financial Figures

Filing Documents

From the Filing

SC 13G/A 1 d10943920_13g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Alaunos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98973P101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 98973P101 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Discovery Capital Management, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [x] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Connecticut NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 4,001,856 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 4,001,856 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,001,856 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.66% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA CUSIP No. 98973P101 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Robert K. Citrone 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [x] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 4,001,856 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 4,001,856 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,001,856 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.66% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN, HC CUSIP No. 98973P101 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Discovery Global Opportunity Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [x] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 4,001,856 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 4,001,856 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,001,856 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.66% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 98973P101 Item 1. (a). Name of Issuer: Alaunos Therapeutics, Inc. (b). Address of Issuer's Principal Executive Offices: 8030 El Rio Street Houston, Texas 77054 Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing: Discovery Capital Management, LLC – Connecticut Robert K. Citrone – U.S.A. Discovery Global Opportunity Master Fund, Ltd. – Cayman Islands Discovery Capital Management, LLC 20 Marshall Street, Suite 310 South Norwalk, CT 06854 United States of America Robert K. Citrone c/o Discovery Capital Management, LLC 20 Marshall Street, Suite 310 South Norwalk, CT 06854 United States of America Discovery Global Opportunity Master Fund, Ltd. c/o Discovery Capital Management, LLC 20 Marshall Street, Suite 310 South Norwalk, CT 06854 United States of America (d). Title of Class of Securities: Common Stock, par value $0.001 per share (e). CUSIP Number: 98973P101 Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c). (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c). (c)

View Full Filing

View this SC 13G/A filing on SEC EDGAR

View on Read The Filing